[e Gongsi Notice Catches Attention] KOSDAQ - 21st

Published 22 Mar.2022 06:59(KST)

◆ CrystalGenomics = Announced the voluntary withdrawal application for the domestic Phase 2 clinical trial plan (IND) to evaluate the efficacy and safety of treatment for moderate to severe COVID-19 patients. The company received feedback from the Korean Ministry of Food and Drug Safety indicating a lack of data simultaneously demonstrating both antiviral and anti-inflammatory effects in the non-clinical trial data. Despite ongoing consultations, the differences in opinion could not be resolved.

◆ SD System = Due to a scope limitation in the audit of last year's financial statements, the company received a "qualified" opinion, resulting in grounds for delisting. The company may file an objection to the delisting notice by the 11th of next month. The exchange plans to review and decide by combining the audit opinions for the 2020 fiscal year and the interim audit opinion for the 2021 fiscal year regarding delisting grounds.

◆ Seowon Intech = Announced that the submission of the disclosure will be delayed as the external auditor has not received sufficient evidence to issue the audit report.

◆ Osstem Implant = Regarding the announcement of embezzlement and breach of trust charges in January, the company was designated for a substantive review of listing eligibility. They additionally disclosed the fact of "impairment losses arising from receivables other than accounts receivable," thereby adding another reason for the substantive review of listing eligibility.

◆ UCI = Due to a scope limitation in the audit of last year's financial statements and uncertainty about the company's ability to continue as a going concern, the company received a "disclaimer of opinion," resulting in grounds for delisting. The company may file an objection to the delisting notice by the 11th of next month. The exchange plans to review and decide by combining the audit opinions for the 2020 fiscal year and the interim audit opinion for the 2021 fiscal year regarding delisting grounds.

◆ Ginaine Pharm = Announced that a delay in loan repayment of 500 million KRW occurred due to a shortage of operating funds. The company also disclosed that there are other overdue principal and interest payments on loans.